| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | DBM |
| WB Predicted band size | 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DBH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DBH(多巴胺β-羟化酶)抗体的参考文献示例(内容为模拟生成，非真实文献)：
---
1. **文献名称**: *"Immunohistochemical localization of dopamine β-hydroxylase in human adrenal medulla and pheochromocytoma"*
**作者**: Cubells, J. F., et al.
**摘要**: 研究通过DBH抗体标记人肾上腺髓质和嗜铬细胞瘤中的多巴胺β-羟化酶分布，证实DBH在儿茶酚胺合成中的关键作用，并探讨其在神经内分泌肿瘤诊断中的应用价值。
---
2. **文献名称**: *"Genetic variants of DBH and their association with cardiovascular diseases"*
**作者**: Kobayashi, K., & Kurosawa, Y.
**摘要**: 分析DBH基因多态性与高血压及心血管疾病的关联，利用DBH抗体检测血浆酶活性水平，发现特定单核苷酸多态性(SNP)与DBH活性降低及疾病风险增加相关。
---
3. **文献名称**: *"Development of monoclonal antibodies against dopamine β-hydroxylase for neurodegenerative disease research"*
**作者**: Smith, A. D., et al.
**摘要**: 描述新型DBH单克隆抗体的开发与验证，证明其在帕金森病动物模型中特异性标记去甲肾上腺素能神经元的能力，为神经退行性病变研究提供工具。
---
4. **文献名称**: *"DBH deficiency in mice: Behavioral and biochemical characterization using antibody-based assays"*
**作者**: Thomas, S. A., & Palmiter, R. D.
**摘要**: 利用DBH抗体研究DBH基因敲除小鼠模型，发现其去甲肾上腺素缺失导致自主神经功能异常及认知障碍，揭示DBH在神经行为调节中的重要性。
---
注：以上文献为示例性质，实际引用请通过学术数据库(如PubMed)检索真实发表的研究。
**Background of DBH Antibodies**
Dopamine β-hydroxylase (DBH) is a critical enzyme in the catecholamine biosynthesis pathway, catalyzing the conversion of dopamine to norepinephrine. Primarily located in the adrenal medulla and sympathetic nerve terminals, DBH is essential for maintaining sympathetic nervous system function and regulating cardiovascular, metabolic, and stress responses. DBH antibodies target this enzyme and are widely used in research and diagnostics to study catecholaminergic systems.
DBH dysfunction has been implicated in cardiovascular disorders (e.g., hypertension), neurodegenerative diseases (e.g., Parkinson’s), and psychiatric conditions (e.g., schizophrenia). Antibodies against DBH enable the detection of enzyme levels in tissues or bodily fluids, aiding in the diagnosis of neuroendocrine tumors like pheochromocytoma or paraganglioma. They also serve as tools to explore DBH’s role in autonomic dysfunction or genetic variations affecting enzyme activity.
In research, DBH antibodies are employed in techniques such as ELISA, immunohistochemistry, and Western blotting to map catecholaminergic pathways, assess DBH expression in disease models, or validate gene-editing outcomes. Notably, reduced DBH activity, linked to specific polymorphisms, is associated with cognitive and behavioral traits, highlighting its broader physiological relevance.
Overall, DBH antibodies are pivotal in elucidating the enzyme’s biological and pathological roles, bridging insights into neurotransmission, disease mechanisms, and therapeutic targeting.
×
